Published in Stem Cell Rev on December 01, 2010
Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models. Nat Neurosci (2012) 1.86
Mesenchymal stem cells: from experiment to clinic. Fibrogenesis Tissue Repair (2011) 1.13
Reduced inflammation accompanies diminished myelin damage and repair in the NG2 null mouse spinal cord. J Neuroinflammation (2011) 1.09
The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. Immunotherapy (2012) 0.88
Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. Expert Rev Neurother (2011) 0.87
Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis. Stem Cells Transl Med (2012) 0.87
Intracerebral transplantation for neurological disorders. Lessons from developmental, experimental, and clinical studies. Front Cell Neurosci (2012) 0.84
Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. ASN Neuro (2011) 0.84
Hyaluronan and fibrin biomaterial as scaffolds for neuronal differentiation of adult stem cells derived from adipose tissue and skin. Int J Mol Sci (2011) 0.83
Endothelial progenitor cell cotransplantation enhances islet engraftment by rapid revascularization. Diabetes (2012) 0.83
Emerging stem cell therapies: treatment, safety, and biology. Stem Cells Int (2012) 0.83
Stem cell transplantation therapy for multifaceted therapeutic benefits after stroke. Prog Neurobiol (2017) 0.75
Transplantation of mesenchymal stem cells in a laryngeal carcinoma patient with radiation myelitis. Stem Cell Res Ther (2015) 0.75
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol (2010) 2.17
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med (2013) 1.88
The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci (2004) 1.33
The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc Natl Acad Sci U S A (2003) 1.24
CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis--an intravital microscopy study. J Neuroimmunol (2005) 1.18
Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis. Glia (2005) 1.10
Distinct immunomodulatory and migratory mechanisms underpin the therapeutic potential of human mesenchymal stem cells in autoimmune demyelination. Cell Transplant (2012) 1.05
Gender does not influence the susceptibility of C57BL/6 mice to develop chronic experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein. Immunol Lett (2002) 1.05
Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG. J Neuroimmune Pharmacol (2009) 1.03
The prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis. Curr Stem Cell Res Ther (2011) 1.02
Modular transcriptional activity characterizes the initiation and progression of autoimmune encephalomyelitis. J Immunol (2005) 1.01
Regulatory role of p53 in experimental autoimmune encephalomyelitis. J Neuroimmunol (2003) 1.00
TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol Cell Biol (2005) 1.00
Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis. Stem Cell Res (2011) 1.00
Multiple sclerosis: a battle between destruction and repair. J Neurochem (2006) 0.99
Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain (2012) 0.98
B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity. Ann Neurol (2015) 0.98
Alveolar macrophages are critical for the inhibition of allergic asthma by mesenchymal stromal cells. J Immunol (2013) 0.97
A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol (2006) 0.95
Transplantation of bone marrow transduced to express self-antigen establishes deletional tolerance and permanently remits autoimmune disease. J Immunol (2008) 0.94
The suppression of T cell apoptosis influences the severity of disease during the chronic phase but not the recovery from the acute phase of experimental autoimmune encephalomyelitis in mice. J Neuroimmunol (2002) 0.91
Increased transcriptional activity of milk-related genes following the active phase of experimental autoimmune encephalomyelitis and multiple sclerosis. J Immunol (2007) 0.91
The application of Fourier transform infrared microspectroscopy for the study of diseased central nervous system tissue. Neuroimage (2011) 0.88
Early glial responses in murine models of multiple sclerosis. Neurochem Int (2004) 0.87
Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. J Med Chem (2011) 0.87
The promise of stem cell and regenerative therapies for multiple sclerosis. J Autoimmun (2008) 0.86
Early detection of the chemical changes occurring during the induction and prevention of autoimmune-mediated demyelination detected by FT-IR imaging. Neuroimage (2009) 0.86
The magnitude and encephalogenic potential of autoimmune response to MOG is enhanced in MOG deficient mice. J Autoimmun (2003) 0.86
Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination. Cell Adh Migr (2012) 0.86
Novel therapeutic targets for axonal degeneration in multiple sclerosis. J Neuropathol Exp Neurol (2010) 0.85
Functional properties of myelin oligodendrocyte glycoprotein-reactive T cells in multiple sclerosis patients and controls. J Neuroimmunol (2003) 0.84
Comparative study on the therapeutic potential of neurally differentiated stem cells in a mouse model of multiple sclerosis. PLoS One (2012) 0.84
IL-5-deficient mice are susceptible to experimental autoimmune encephalomyelitis. Int Immunol (2003) 0.84
Microglial cystatin F expression is a sensitive indicator for ongoing demyelination with concurrent remyelination. J Neurosci Res (2011) 0.84
Human adipose-derived mesenchymal stem cells engineered to secrete IL-10 inhibit APC function and limit CNS autoimmunity. Brain Behav Immun (2013) 0.83
Quantitative proteome profiling of CNS-infiltrating autoreactive CD4+ cells reveals selective changes during experimental autoimmune encephalomyelitis. J Proteome Res (2014) 0.80
Quantitative and phenotypic analysis of bone marrow-derived cells in the intact and inflamed central nervous system. Cell Adh Migr (2011) 0.79
Lithium chloride improves the efficiency of induced pluripotent stem cell-derived neurospheres. Biol Chem (2015) 0.78
A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseases. Mol Cell Proteomics (2011) 0.77
Nogo-receptor 1 deficiency has no influence on immune cell repertoire or function during experimental autoimmune encephalomyelitis. PLoS One (2013) 0.76